MIGSUN

This brand name is authorized in Estonia

Active ingredients

The drug MIGSUN contains a combination of these active pharmaceutical ingredients (APIs):

1 Sumatriptan UNII 8R78F6L9VO - SUMATRIPTAN
Sumatriptan has been demonstrated to be a specific and selective 5-Hydroxytryptamine₁ (5HT_1D) receptor agonist with no effect on other 5HT receptor (5-HT₂ - 5-HT₇) subtypes. The vascular 5-HT_1D receptor is found predominantly in cranial blood vessels and mediates vasoconstriction. Read about Sumatriptan
2 Naproxen UNII 57Y76R9ATQ - NAPROXEN
Naproxen is a non-steroidal anti-inflammatory analgesic compound with antipyretic properties as has been demonstrated in classical animal test systems. Naproxen exhibits its anti-inflammatory effect even in adrenalectomised animals, indicating that its action is not mediated through the pituitary-adrenal axis. Read about Naproxen

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N02CC	Selective serotonin (5HT1) agonists	N Nervous system → N02 Analgesics → N02C Antimigraine preparations
Discover more medicines within N02CC

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1835805

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.